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Nicola´s Laffaye, MD,* Javier Mariani, MD,* Daniel Ferrante, MD,* Raúl Badra, MD,†
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on behalf of the GESICA Investigators
Buenos Aires, Mar del Plata, and Morón, Argentina; and Santa Maria Imbaro, Italy
Objectives The aim of this study was to evaluate the efficacy of polyunsaturated fatty acids (n-3 PUFA) for the prevention of
recurrent atrial fibrillation (AF) in patients with normal sinus rhythm.
Background Current pharmacological treatments to limit recurrent AF in patients with previous AF have limited efficacy and high
rates of adverse events. Results of trials that tested the efficacy of n-3 PUFA provided heterogeneous results.
Methods This was a prospective, randomized, double-blind, placebo-controlled, multicenter trial involving 586 outpatient
participants with confirmed symptomatic paroxysmal AF that required cardioversion (n  428), at least 2 epi-
sodes of AF in the 6 months before randomization (n  55), or both (103). Patients were randomly allocated to
n-3 PUFA (1 g/day) or placebo for 12 months. The primary endpoint was symptomatic recurrence of AF.
Results There were no significant differences between patients allocated to placebo and those who received n-3 PUFA
for the main outcome. At 12 months, 56 of 297 participants (18.9%) in the placebo group and 69 of 289 partic-
ipants (24.0%) in the n-3 PUFA group had a recurrent symptomatic AF (hazard ratio: 1.28, 95% confidence inter-
val: 0.90 to 1.83, p  0.17). There was no difference between treatment with placebo and n-3 PUFA for any of
the other pre-specified endpoints, including the composite of all-cause mortality, nonfatal stroke, nonfatal acute
myocardial infarction, systemic embolism, heart failure development, or severe bleeding that occurred in 20
(6.7%) and 16 (5.5%) of patients randomized to placebo or n-3 PUFA, respectively (hazard ratio: 0.86, 95% con-
fidence interval: 0.44 to 1.66, p  0.65).
Conclusions Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF. (Random-
ized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation
[FORWARD]; NCT00597220) (J Am Coll Cardiol 2013;61:463–8) © 2013 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.021Atrial fibrillation (AF) is the most common type of arrhyth-
mia in adults, accounting for approximately one-third of
hospital stays for arrhythmia (1). The arrhythmia confers an
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taly; and Sigma Tau, Rome, Italy; but these companies did not have representatives
n the Steering Committee. The authors have reported that they have no relation-
hips relevant to the contents of this paper to disclose.
Manuscript received October 14, 2012; revised manuscript received November 15,012, accepted November 17, 2012.increased risk of death (2), thromboembolism, and impaired
quality of life, even if asymptomatic (3).
Current treatment strategies are less than satisfactory, and
a number of trials and a meta-analysis (4) inform us that we
should be satisfied with ventricular rate control and antico-
agulation. Although many factors might contribute to these
unsatisfactory results, the limited efficacy and the many and
dangerous side effects of antiarrhythmic drugs might be
particularly responsible for this failure (5). In this context,
polyunsaturated fatty acids (n-3 PUFA) emerge as attractive
candidates to manage AF, because these agents have demo-
nstrated benefit by reducing overall mortality (6), mostly
through a decrease in ventricular arrhythmias (7). It has
been speculated that some of these antiarrhythmic proper-
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decrease of atrial arrhythmias (8).
However, results of randomized
clinical trials were heteroge-
neous, with some showing prom-
ising results and others yielding
neutral conclusions (9–14).
We present the results of the FORWARD (Randomized
rial to Assess Efficacy of PUFA for theMaintenance of Sinus
hythm in Persistent Atrial Fibrillation Fish Oil Research
ith omega-3 for Atrial fibrillation Recurrence Delaying), a
andomized, double-blind, placebo-controlled trial assessing
he efficacy of n-3 PUFA supplementation for the mainte-
ance of sinus rhythm in patients with previous AF.
ethods
tudy design. Details of the trial have been previously
ublished (15). Briefly, FORWARD was an independent,
ouble-blind, randomized, controlled trial testing the effi-
acy of pharmacological supplementation with 1 g/day of
Figure 1 Study Flowchart
From screened elegible patients to intention-to-treat analysis. AF  atrial fibrillatio
n-3 PUFA  polyunsaturated fatty acids.
Abbreviations
and Acronyms
AF  atrial fibrillation
n-3 PUFA 
polyunsaturated fatty acids-3 PUFA for 1 year for the maintenance of normal sinus
hythm in patients with previous persistent AF. The study
opulation included men and women 21 years diagnosed
n an outpatient setting with previous symptomatic AF who
ad recovered normal sinus rhythm. For inclusion in the
rial, patients must have had either: 1) 2 symptomatic
pisodes of documented AF in the 6 months before ran-
omization, with the last episode occurring within 3 to 90
ays before randomization (paroxysmal AF); or 2) successful
lectrical or pharmacological cardioversion for persistent AF
erformed within 3 to 28 days before randomization.
To avoid the inclusion of patients with lone AF, all
ubjects 65 years of age must have presented 1 charac-
eristic of moderate-to-high risk of stroke. After providing
nformed consent, patients were centrally assigned in a ratio
f 1:1 to receive either 1 g n-3 PUFA (provided by SPA and
igma-Tau, Italy), which provide 850 to 882 mg eicosapen-
aenoic acid/docosahexaenoic acid ethyl esters, or placebo
olive oil) in a double-blind fashion. Study treatments were
n addition to any other treatments prescribed for AF.
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January 29, 2013:463–8 Omega-3 for Atrial Fibrillation PreventionThe study was conducted according to the Declaration of
Helsinki at 42 Argentinean centers. All centers obtained
institutional review board approval for the study before
participant screening. All participants provided written
informed consent before enrollment and randomization.
Clinical outcomes, adherence, and adverse events were
assessed 2, 4, 8, and 12 months after randomization.
The primary efficacy point was the time to first recurrence
of an AF episode of symptomatic or asymptomatic AF
(documented by a 12-lead electrocardiogram). Secondary
outcomes included: 1) the hierarchical composite of all-
cause mortality, nonfatal stroke, nonfatal acute myocardial
infarction, systemic embolism, heart failure development,
severe bleeding; 2) all-cause hospital stays; 3) survival free of
thromboembolic events; and 4) hospital stays for cardiovas-
cular reasons.
Statistical analysis and sample size calculation. The
event rate for a similar endpoint in patients with AF who
restored normal sinus rhythm was 40% recurrence at 1 year
(16). We originally planned to recruit 1,398 participants.
This would have provide 85% power with a 2-sided alpha
error of 5% to detect a 20% relative reduction at 1 year—
equating to event rates of 40% and 32% in those randomized
to placebo and n-3 PUFA, respectively.
A slower-than-expected recruitment rate and lower event
rates led to ongoing consideration of recruitment and
termination dates by the trial steering committee. Although
the trial had not included any efficacy interim analysis, the
data and safety monitoring board was formally called to
make a formal recommendation about the appropriateness
of continuing recruitment. This committee reviewed the
data and reported to the Steering Committee that a full
complement of planned number of patients would not likely
have led to a positive finding and led to stopping the
recruitment process.
Efficacy comparisons were performed on the basis of time
to the first event, according to the intention-to-treat prin-
ciple, including all patients in the group to which they were
randomized, with patients lost to follow-up censored at the
day of the last visit. Safety analyses were performed on data
from all enrolled patients. We used the Cox proportional
hazards model to estimate hazard ratios (HRs) along with
95% confidence intervals (CIs). All analyses were performed
with SAS (version 9.1, SAS Institute, Inc., Cary, North
Carolina) and with SPSS (version 16.0 for Windows, SPSS,
Inc., Chicago, Illinois).
Results
A total of 586 participants with confirmed symptomatic AF
were recruited from January 2008 to March 2011. Of these,
428 required cardioversion, 55 had 2 episodes of AF
ithin 6 months before randomization, and 103 met both
riteria.
Of the 586 patients randomized, 541 (92.3%) completedhe study. Premature withdrawals occurred in 45 patientsand were comparable across treatment groups, with the
most frequent reason being consent withdrawal (n  31),
ollowed by gastrointestinal intolerance (n  14) (Fig. 1).
Demographic, clinical, and treatment characteristics were
similar between both treatment groups (Table 1).
tudy outcomes. There were no statistical differences be-
ween patients randomized to placebo or to n-3 PUFA for
he primary endpoint. At the end of follow-up, 56 of 297
articipants (18.9%) in the placebo group and 69 of 289
articipants (24.0%) in the n-3 PUFA group had recurrent
Summary of Main Baseline CharacteristicsTable 1 Summary of Main Baseline Characteristics
Overall
(N  586)
Placebo
(n  297)
n-3 PUFA
(n  289)
p
Value
Age, yrs 66.1 11.3 65.9 10.5 66.3 12.0 0.685
Men 321 (54.8) 154 (51.9) 167 (57.8) 0.159
Recruitment criteria
Cardioversion 428 (73.0) 212 (71.4) 216 (74.7) 0.475
2 episodes 6 months 55 (9.4) 32 (10.8) 23 (8.0)
Both 103 (17.6) 53 (17.8) 50 (17.3)
Clinical features
Hypertension 524 (91.4) 265 (90.8) 259 (92.2) 0.554
Diabetes 74 (12.9) 43 (14.7) 31 (11.1) 0.214
High cholesterol 265 (46.7) 146 (50.7) 119 (42.7) 0.064
Nonsmoker 328 (57.8) 167 (57.8) 161 (57.9) 0.412
Smoker: current 43 (7.6) 18 (6.2) 25 (9.0)
Smoker: past 196 (34.6) 104 (36.0) 92 (33.1)
Chronic heart failure 81 (14.1) 42 (14.3) 39 (13.9) 0.905
Stroke 27 (4.7) 13 (4.4) 14 (5.0) 0.844
Peripheral vascular
disease
14 (2.4) 8 (2.7) 6 (2.1) 0.789
Coronary artery disease 67 (11.7) 31 (10.6) 36 (12.9) 0.436
Renal failure 13 (2.3) 6 (2.1) 7 (2.5) 0.784
Episodes of AF in
6 months
1.61 1.75 1.65 1.90 1.56 1.59 0.561
Echocardiogram features
LA area 29.1 9.9 28.7 10.1 29.7 9.8 0.497
LVEDD 49.6 7.2 49.6 6.8 49.6 7.6 0.932
LVESD 31 7.5 31 7.4 31 7.5 0.986
Ejection fraction 60 10 60 10 60 11 0.963
Laboratory assessments at
baseline
Hemoglobin 13.7 1.6 13.7 1.6 13.7 1.6 0.725
Sodium 139.4 3.7 139.5 3.8 139.2 3.5 0.364
Potassium 4.1 0.5 4.1 0.5 4.1 0.5 0.807
Creatinine 1.43 1.77 1.40 1.6 1.45 1.9 0.762
Anthropometric features
Heart rate, beats/min 64 11 64 10 64 11 0.966
Weight, kg 82 17 83 19 81 16 0.137
Treatment at baseline
Aspirin 298 (50.9) 158 (53.2) 140 (48.4) 0.283
Anticoagulation 247 (42.2) 125 (42.1) 122 (42.2) 1.000
Amiodarone 372 (63.5) 189 (63.6) 183 (63.3) 1.000
Any antithrombotic
treatment
455 (77.6) 232 (78.1) 223 (77.2) 0.843
Beta-blockers 353 (60.2) 176 (60.5) 177 (62.5) 0.668
Values are mean  SD or n (%).
AF atrial fibrillation; LA left atrium; LVEDD left ventricular end-diastolic diameter; LVESD left
ventricular end-systolic diameter; n-3 PUFA  polyunsaturated fatty acids.
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0.17) (Fig. 2). Additionally, 5 patients (1.7%) in the placebo
group and 4 (1.4%) in the n-3 PUFA group died during the
study (HR: 0.80, 95% CI: 0.21 to 3.00, p  0.74).
The composite of all-cause mortality, nonfatal stroke,
nonfatal acute myocardial infarction, systemic embolism,
heart failure development, or severe bleeding occurred in 20
(6.7%) and 16 (5.5%) of patients randomized to placebo or
n-3 PUFA, respectively (HR: 0.86, 95% CI: 0.44 to 1.66,
p  0.65).
The lack of statistically significant differences between
patients randomized to placebo and n-3 PUFA were ob-
served in all study outcomes (Table 2). Additionally, all
pre-specified subgroup analyses yielded similar results for all
tested outcomes. Particularly, the mean effect of n-3 PUFA
for prevention of AF recurrence was similar in patients who
previously received antiarrhythmic agents (HR: 1.22, 95%
CI: 0.78 to 1.91) and those without previous treatment
(HR: 1.41, 95% CI: 0.79 to 2.52). Other pre-specified
subgroup analyses, including elderly patients, women, and
Figure 2 Primary Efficacy Endpoint
Time to first recurrence of symptomatic atrial fibrillation (AF). HR  hazard ratio;
n-3 PUFA  polyunsaturated fatty acids.
Summary of Primary and Secondary Efficacy ResultsTable 2 Su mary of Primary and Secondary Efficacy Results
Overall (n  586) Place
Recurrent AF 125 (21.4)
Death 9 (1.5)
Composite endpoint* 36 (6.1)
Thromboembolic event 17 (2.9)
All-cause hospital stay 90 (15.4)
Hospital stay for AMI 2 (0.3)
Hospital stay for stroke 6 (1.0)
Hospital stay for CHF† 11 (1.9)
Values are n (%). *Composite of first occurrence of either all-cause mortality, nonfatal stroke, nonfa
†Among patients with no congestive heart failure (CHF) at baseline.
AF  atrial fibrillation; CI  confidence interval; HR  hazard ratio; n-3 PUFA  polyunsaturated fattypatients with different duration of previous AF, yielded
similar results (Fig. 3). Among the 428 patients that were
recruited because of a single episode of AF that required
cardioversion, the recurrence rate was 20.6% (88 of 428). By
contrast, in the remaining 158 patients, the recurrence rate
was 23.4% (37 of the 158 patients). This difference was not
statistically significant (p  0.496). If we considered, not
proportion, but time to event, the differences remains
statistically not significant (p  0.515).
Few patients discontinued experimental treatment due to
intolerance. Specifically, 2.7% of those randomized to pla-
cebo and 2.0% of those allocated to n-3 PUFA early
abandoned treatment for gastrointestinal intolerance. Addi-
tionally, 5.7% in the placebo arm and 4.8% in the n-3
PUFA group withdrew consent during the study. None of
these patients reported clinical events.
Nine patients died during the study; no deaths were
considered related to treatment.
Discussion
The results reported here could be interpreted from at least
2 perspectives. The first and more direct interpretation
would be that the early stoppage of the FORWARD trial
resulted in an underpowered clinical trial unable to verify its
hypothesis. However, in absolute terms, the trial captured
the second largest number of events among all trials ever
conducted in patients with AF (9–14) with n-3 PUFA.
When the study was terminated, few patients had experi-
enced clinical events, and the estimation of the effect of n-3
PUFA resulted in no statistically significant reductions of
any of the clinical outcomes tested, including AF recur-
rence, death, hospital stay for any reason, and the composite
endpoints.
The low frequency of events could have been the result of
several factors. First, the population recruited had a low risk
of AF recurrence at recruitment, mainly because most
patients (73%) had only experienced a single episode of AF
that required cardioversion; the remaining patients had
experienced at least 2 episodes of AF within 6 months
preceding randomization. Second, a high proportion of
patients (63%) received prophylaxis with amiodarone at the
 297) n-3 PUFA (n  289) HR (95% CI)
.9) 69 (23.9) 1.28 (0.90–1.83)
) 4 (1.4) 0.80 (0.21–3.00)
) 16 (5.5) 0.86 (0.44–1.66)
) 7 (2.4) 0.79 (0.30–2.07)
.1) 48 (16.6) 1.22 (0.81–1.85)
) 1 (0.3) 1.10 (0.07–17.9)
) 3 (1.0) 1.16 (0.23–5.78)
) 5 (1.7) 0.86 (0.26–2.81)
te myocardial infarction (AMI), systemic embolism, heart failure development, or severe bleeding.bo (n
56 (18
5 (1.7
20 (6.7
10 (3.4
42 (14
1 (0.3
3 (1.0
6 (2.0
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January 29, 2013:463–8 Omega-3 for Atrial Fibrillation Preventiontime of inclusion. Although the FORWARD trial was a
pragmatic clinical trial that allowed the use of any other
antiarrhythmic agent, this high proportion of patients who
received amiodarone possibly explains the lower-than-
expected rate of events. Finally, the identification of patients
with recurrent AF was done with clinical criteria and not
trans-telephonic monitoring, which might have resulted in a
difference in detection of events.
The second interpretation of the results of the
FORWARD trial is in the perspective of all randomized
clinical trials evaluating n-3 PUFA supplementation for the
prevention of recurrent AF. Although both the
FORWARD and Kowey et al. (10) trials stopped before
fully enrolling their intended patient populations, together
they contributed 70% of patients and events in clinical
esearch of this question and might constitute a refutation of
he hypothesis of a protective role of these agents for this
ndication.
The dose used in this trial was quantitatively and quali-
atively similar to that effective in the GISSI Prevenzione
rial (6) and was deemed appropriate, because of the balance
etween proved therapeutic action and good tolerance and
dherence. It could be that higher doses would have resulted
n more efficient prevention of recurrent AF; however, trials
hat used larger doses provided results materially similar to
hose reported here (10). It should be acknowledged as a
imitation that we did not track fish consumption among
articipants. It could be that high fish intake might have
itigated the effect of oral supplementation. Although this
s possible, it should also be noted that fish intake is
Figure 3 Sub-Groups Analysis
Results on pre-specified sub-groups of patients. CI  confidence interval; other abow-to-very-low in Argentina.onclusions
he FORWARD trial found no significant differences
etween n-3 PUFA supplementation and placebo in pre-
ention of AF recurrence.
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